← Back to all trials
Enrolling By Invitation
NCT06873035
An Interventional Study of Infigratinib in Children With Hypochondroplasia
Conditions: Hypochondroplasia
Sex: All
Ages: 3 Years – 18 Years
Healthy volunteers: No
Phase: PHASE2, PHASE3
Enrollment: 24
Sponsor: QED Therapeutics, a BridgeBio company
Location: UCSF Benioff Children's Hospital Oakland California
Summary
ACCEL2/3 is a Phase 2/3 study. The purpose of the Phase 2 portion of the study (ACCEL2/3) is to evaluate the efficacy and safety of infigratinib in children with hypochondroplasia (HCH) receiving infigratinib at one of two doses, who have completed at least 26 weeks of participation in QED-sponsored ACCEL (QBGJ398-004).
Eligibility Criteria
Key Inclusion Criteria:
* Participants must have completed at least 26 weeks and still be on the observational study (QBGJ398-004).
* Phase 2 portion: Participants 5-11 years of age (inclusive).
* Phase 3 portion: Participants 3 to \
Source: ClinicalTrials.gov (NCT06873035). StuddyBuddy aggregates publicly available trial information.
